+Follow
Bencessco
No personal profile
0
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
Bencessco
2021-04-21
...
Will Regeneron's COVID Cocktail Win Be Short-Lived?
Bencessco
2021-04-21
Wao
3 Stocks That Could Make You Rich
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582073255338801","uuid":"3582073255338801","gmtCreate":1618980983611,"gmtModify":1618980983611,"name":"Bencessco","pinyin":"bencessco","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":378164573,"gmtCreate":1619011996292,"gmtModify":1704718259062,"author":{"id":"3582073255338801","authorId":"3582073255338801","name":"Bencessco","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582073255338801","authorIdStr":"3582073255338801"},"themes":[],"htmlText":"... ","listText":"... ","text":"...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378164573","repostId":"2129875413","repostType":4,"repost":{"id":"2129875413","pubTimestamp":1619001180,"share":"https://ttm.financial/m/news/2129875413?lang=&edition=fundamental","pubTime":"2021-04-21 18:33","market":"us","language":"en","title":"Will Regeneron's COVID Cocktail Win Be Short-Lived?","url":"https://stock-news.laohu8.com/highlight/detail?id=2129875413","media":"Motley Fool","summary":"The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.","content":"<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this <i>Motley Fool Live</i> video <b>recorded on April 14, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.</p><p><b>Keith Speights:</b> Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.</p><p>The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.</p><p>These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?</p><p><b>Brian Orelli:</b> Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.</p><p>But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.</p><p>The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.</p><p><b>Speights:</b> I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.</p><p><b>Orelli:</b> Not late-stage failure certainly. I can't think of any failures that they've had.</p><p><b>Speights:</b> The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Regeneron's COVID Cocktail Win Be Short-Lived?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Regeneron's COVID Cocktail Win Be Short-Lived?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 18:33 GMT+8 <a href=https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"source_url":"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129875413","content_text":"Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.Keith Speights: Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?Brian Orelli: Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.Speights: I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.Orelli: Not late-stage failure certainly. I can't think of any failures that they've had.Speights: The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378164056,"gmtCreate":1619011957875,"gmtModify":1704718260204,"author":{"id":"3582073255338801","authorId":"3582073255338801","name":"Bencessco","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582073255338801","authorIdStr":"3582073255338801"},"themes":[],"htmlText":"Wao","listText":"Wao","text":"Wao","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378164056","repostId":"2129713088","repostType":4,"repost":{"id":"2129713088","pubTimestamp":1619007900,"share":"https://ttm.financial/m/news/2129713088?lang=&edition=fundamental","pubTime":"2021-04-21 20:25","market":"us","language":"en","title":"3 Stocks That Could Make You Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2129713088","media":"Motley Fool","summary":"Agriscience, air conditioning, and infrastructure consulting companies can make investors a lot of money in the coming years.","content":"<p>With stock price rises of 76% to 209% over the last year, agriscience experts <b>Corteva</b> (NYSE:CTVA), engineering consultancy <b>AECOM</b> (NYSE:ACM), and heating, ventilation, and air-conditioning experts (HVAC) company <b>Carrier Global</b> (NYSE:CARR) have arguably already made investors rich. However, I think there could be a lot more to come from all three in the coming years. Here's why.</p><h2>Why Corteva can make you rich</h2><p>Corteva was created out of the DowDuPont merger. DuPont's expertise in seeds was combined with Dow's crop protection specialty to create a company that generates around 55% of its sales from seeds and traits and 45% from crop protection. The investment case for the stock rests on the three interrelated factors.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621509%2Fsoybean-crops.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><p>First, management will continue to execute its plan to cut structural costs and enhance productivity following the merger. For example, Corteva generated $230 million in cost and productivity actions in 2020, and management expects a further $250 million in 2021. For reference, operating earnings before interest, taxation, depreciation, and amortization (EBITDA) was $2.1 billion in 2020, so these cost actions are significant and help to enable growth investments.</p><p>Second, Corteva has a significant opportunity to expand profit margins by reducing its royalty payments to other companies as it grows the share of its seed sales coming from seeds using its own germplasm and in-licensed traits. Management sees an opportunity to cut royalty payments by $400 million over time. Also, Corteva plans to significantly increase the share of its crop protection sales coming from patented and \"differentiated\" sources from 14% and 10% in 2018 to 34% and 16% by 2023 -- something that should increase the quality of its earnings and give it more pricing power.</p><p>Third, Corteva aims to grow sales of its Enlist soybean seeds and crop protection system. Competition is fierce, but management believes it can achieve a 50% market share over time compared to 20% share in 2020.</p><p>All told, the company has plenty of revenue and margin expansion opportunities, and analysts expect it to increase EBITDA by 50% to more than $3 billion by 2023, potentially putting the stock at an enterprise value (market cap plus debt) to EBITDA multiple of 10 times EBITDA in 2023. That's an excellent multiple for a stock with double-digit earnings growth prospects.</p><h2>Why AECOM can make you rich</h2><p>The case for engineering consultancy AECOM rests on a combination of confidence that an infrastructure bill will boost its long-term growth prospects and that its restructuring plan will be executed successfully.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621509%2Fgettyimages-117751351.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"423\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><p>AECOM's three biggest end markets are transportation, facilities, and environment and water. As such, it's a play on an infrastructure bill not least as the U.S. needs to upgrade roads, transportation facilities, bridges, dams, and other water infrastructure. Also, increasing environmental regulation ensures long-term demand growth for AECOM's environmental services.</p><p>AECOM has a growth opportunity through its ongoing plan to slim down and focus on its core competencies. It's a playbook established by its peer <b>Jacobs Engineering Group</b>, and if AECOM can achieve its aim, then there's no reason why it can't close the valuation gap with Jacobs.</p><p><img src=\"https://media.ycharts.com/charts/032724028bc48be77d7f9fad331cdba6.png\" tg-width=\"720\" tg-height=\"435\" referrerpolicy=\"no-referrer\"></p><p>Data by YCharts</p><h2>Why Carrier Global can make you rich</h2><p>Leading HVAC company Carrier Global came out of the former United Technologies. The case for the stock hinges on the company's ability to cut costs and grow revenue.</p><p>Management is on track with its so-called \"Carrier 700\" plan to cut $700 million from annual costs by 2022. The cost cuts will come from consolidating and shifting toward low-cost suppliers, lowering factory costs by increasing automated production, and lowering administrative costs by increasing the number of employees performing shared service roles.</p><p>Still, it's not just about cost-cutting. Carrier has plenty of growth opportunities. The coronavirus pandemic has led to a surge in residential orders, and higher-quality HVAC providers have a growth opportunity from commercial customers looking to increase air quality and ventilation in their buildings in a post-pandemic world.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621509%2Fcomm-buildings.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"503\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><p>Also, the HVAC industry's leading players have an opportunity to increase equipment and service sales through the adoption of digital technologies that should improve service levels. Meanwhile, rising global temperatures (particularly in cities as urbanization occurs), increasing regulatory requirements, and the growth of the middle class in emerging economies should all support long-term HVAC demand.</p><p>Analysts have the company trading at an enterprise value to EBITDA multiple of 12.8 times in 2022, when the Carrier 700 plan ends. That's a good value for a company with high-single-digit earnings growth potential.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Make You Rich</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Make You Rich\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 20:25 GMT+8 <a href=https://www.fool.com/investing/2021/04/21/3-stocks-that-could-make-you-rich/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With stock price rises of 76% to 209% over the last year, agriscience experts Corteva (NYSE:CTVA), engineering consultancy AECOM (NYSE:ACM), and heating, ventilation, and air-conditioning experts (...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/3-stocks-that-could-make-you-rich/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACM":"Aecom Technology Corporation"},"source_url":"https://www.fool.com/investing/2021/04/21/3-stocks-that-could-make-you-rich/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129713088","content_text":"With stock price rises of 76% to 209% over the last year, agriscience experts Corteva (NYSE:CTVA), engineering consultancy AECOM (NYSE:ACM), and heating, ventilation, and air-conditioning experts (HVAC) company Carrier Global (NYSE:CARR) have arguably already made investors rich. However, I think there could be a lot more to come from all three in the coming years. Here's why.Why Corteva can make you richCorteva was created out of the DowDuPont merger. DuPont's expertise in seeds was combined with Dow's crop protection specialty to create a company that generates around 55% of its sales from seeds and traits and 45% from crop protection. The investment case for the stock rests on the three interrelated factors.Image source: Getty Images.First, management will continue to execute its plan to cut structural costs and enhance productivity following the merger. For example, Corteva generated $230 million in cost and productivity actions in 2020, and management expects a further $250 million in 2021. For reference, operating earnings before interest, taxation, depreciation, and amortization (EBITDA) was $2.1 billion in 2020, so these cost actions are significant and help to enable growth investments.Second, Corteva has a significant opportunity to expand profit margins by reducing its royalty payments to other companies as it grows the share of its seed sales coming from seeds using its own germplasm and in-licensed traits. Management sees an opportunity to cut royalty payments by $400 million over time. Also, Corteva plans to significantly increase the share of its crop protection sales coming from patented and \"differentiated\" sources from 14% and 10% in 2018 to 34% and 16% by 2023 -- something that should increase the quality of its earnings and give it more pricing power.Third, Corteva aims to grow sales of its Enlist soybean seeds and crop protection system. Competition is fierce, but management believes it can achieve a 50% market share over time compared to 20% share in 2020.All told, the company has plenty of revenue and margin expansion opportunities, and analysts expect it to increase EBITDA by 50% to more than $3 billion by 2023, potentially putting the stock at an enterprise value (market cap plus debt) to EBITDA multiple of 10 times EBITDA in 2023. That's an excellent multiple for a stock with double-digit earnings growth prospects.Why AECOM can make you richThe case for engineering consultancy AECOM rests on a combination of confidence that an infrastructure bill will boost its long-term growth prospects and that its restructuring plan will be executed successfully.Image source: Getty Images.AECOM's three biggest end markets are transportation, facilities, and environment and water. As such, it's a play on an infrastructure bill not least as the U.S. needs to upgrade roads, transportation facilities, bridges, dams, and other water infrastructure. Also, increasing environmental regulation ensures long-term demand growth for AECOM's environmental services.AECOM has a growth opportunity through its ongoing plan to slim down and focus on its core competencies. It's a playbook established by its peer Jacobs Engineering Group, and if AECOM can achieve its aim, then there's no reason why it can't close the valuation gap with Jacobs.Data by YChartsWhy Carrier Global can make you richLeading HVAC company Carrier Global came out of the former United Technologies. The case for the stock hinges on the company's ability to cut costs and grow revenue.Management is on track with its so-called \"Carrier 700\" plan to cut $700 million from annual costs by 2022. The cost cuts will come from consolidating and shifting toward low-cost suppliers, lowering factory costs by increasing automated production, and lowering administrative costs by increasing the number of employees performing shared service roles.Still, it's not just about cost-cutting. Carrier has plenty of growth opportunities. The coronavirus pandemic has led to a surge in residential orders, and higher-quality HVAC providers have a growth opportunity from commercial customers looking to increase air quality and ventilation in their buildings in a post-pandemic world.Image source: Getty Images.Also, the HVAC industry's leading players have an opportunity to increase equipment and service sales through the adoption of digital technologies that should improve service levels. Meanwhile, rising global temperatures (particularly in cities as urbanization occurs), increasing regulatory requirements, and the growth of the middle class in emerging economies should all support long-term HVAC demand.Analysts have the company trading at an enterprise value to EBITDA multiple of 12.8 times in 2022, when the Carrier 700 plan ends. That's a good value for a company with high-single-digit earnings growth potential.","news_type":1},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":378164573,"gmtCreate":1619011996292,"gmtModify":1704718259062,"author":{"id":"3582073255338801","authorId":"3582073255338801","name":"Bencessco","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582073255338801","authorIdStr":"3582073255338801"},"themes":[],"htmlText":"... ","listText":"... ","text":"...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378164573","repostId":"2129875413","repostType":4,"repost":{"id":"2129875413","pubTimestamp":1619001180,"share":"https://ttm.financial/m/news/2129875413?lang=&edition=fundamental","pubTime":"2021-04-21 18:33","market":"us","language":"en","title":"Will Regeneron's COVID Cocktail Win Be Short-Lived?","url":"https://stock-news.laohu8.com/highlight/detail?id=2129875413","media":"Motley Fool","summary":"The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.","content":"<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this <i>Motley Fool Live</i> video <b>recorded on April 14, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.</p><p><b>Keith Speights:</b> Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.</p><p>The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.</p><p>These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?</p><p><b>Brian Orelli:</b> Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.</p><p>But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.</p><p>The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.</p><p><b>Speights:</b> I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.</p><p><b>Orelli:</b> Not late-stage failure certainly. I can't think of any failures that they've had.</p><p><b>Speights:</b> The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Regeneron's COVID Cocktail Win Be Short-Lived?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Regeneron's COVID Cocktail Win Be Short-Lived?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 18:33 GMT+8 <a href=https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"source_url":"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129875413","content_text":"Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.Keith Speights: Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?Brian Orelli: Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.Speights: I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.Orelli: Not late-stage failure certainly. I can't think of any failures that they've had.Speights: The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378164056,"gmtCreate":1619011957875,"gmtModify":1704718260204,"author":{"id":"3582073255338801","authorId":"3582073255338801","name":"Bencessco","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582073255338801","authorIdStr":"3582073255338801"},"themes":[],"htmlText":"Wao","listText":"Wao","text":"Wao","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378164056","repostId":"2129713088","repostType":4,"repost":{"id":"2129713088","pubTimestamp":1619007900,"share":"https://ttm.financial/m/news/2129713088?lang=&edition=fundamental","pubTime":"2021-04-21 20:25","market":"us","language":"en","title":"3 Stocks That Could Make You Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2129713088","media":"Motley Fool","summary":"Agriscience, air conditioning, and infrastructure consulting companies can make investors a lot of money in the coming years.","content":"<p>With stock price rises of 76% to 209% over the last year, agriscience experts <b>Corteva</b> (NYSE:CTVA), engineering consultancy <b>AECOM</b> (NYSE:ACM), and heating, ventilation, and air-conditioning experts (HVAC) company <b>Carrier Global</b> (NYSE:CARR) have arguably already made investors rich. However, I think there could be a lot more to come from all three in the coming years. Here's why.</p><h2>Why Corteva can make you rich</h2><p>Corteva was created out of the DowDuPont merger. DuPont's expertise in seeds was combined with Dow's crop protection specialty to create a company that generates around 55% of its sales from seeds and traits and 45% from crop protection. The investment case for the stock rests on the three interrelated factors.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621509%2Fsoybean-crops.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><p>First, management will continue to execute its plan to cut structural costs and enhance productivity following the merger. For example, Corteva generated $230 million in cost and productivity actions in 2020, and management expects a further $250 million in 2021. For reference, operating earnings before interest, taxation, depreciation, and amortization (EBITDA) was $2.1 billion in 2020, so these cost actions are significant and help to enable growth investments.</p><p>Second, Corteva has a significant opportunity to expand profit margins by reducing its royalty payments to other companies as it grows the share of its seed sales coming from seeds using its own germplasm and in-licensed traits. Management sees an opportunity to cut royalty payments by $400 million over time. Also, Corteva plans to significantly increase the share of its crop protection sales coming from patented and \"differentiated\" sources from 14% and 10% in 2018 to 34% and 16% by 2023 -- something that should increase the quality of its earnings and give it more pricing power.</p><p>Third, Corteva aims to grow sales of its Enlist soybean seeds and crop protection system. Competition is fierce, but management believes it can achieve a 50% market share over time compared to 20% share in 2020.</p><p>All told, the company has plenty of revenue and margin expansion opportunities, and analysts expect it to increase EBITDA by 50% to more than $3 billion by 2023, potentially putting the stock at an enterprise value (market cap plus debt) to EBITDA multiple of 10 times EBITDA in 2023. That's an excellent multiple for a stock with double-digit earnings growth prospects.</p><h2>Why AECOM can make you rich</h2><p>The case for engineering consultancy AECOM rests on a combination of confidence that an infrastructure bill will boost its long-term growth prospects and that its restructuring plan will be executed successfully.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621509%2Fgettyimages-117751351.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"423\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><p>AECOM's three biggest end markets are transportation, facilities, and environment and water. As such, it's a play on an infrastructure bill not least as the U.S. needs to upgrade roads, transportation facilities, bridges, dams, and other water infrastructure. Also, increasing environmental regulation ensures long-term demand growth for AECOM's environmental services.</p><p>AECOM has a growth opportunity through its ongoing plan to slim down and focus on its core competencies. It's a playbook established by its peer <b>Jacobs Engineering Group</b>, and if AECOM can achieve its aim, then there's no reason why it can't close the valuation gap with Jacobs.</p><p><img src=\"https://media.ycharts.com/charts/032724028bc48be77d7f9fad331cdba6.png\" tg-width=\"720\" tg-height=\"435\" referrerpolicy=\"no-referrer\"></p><p>Data by YCharts</p><h2>Why Carrier Global can make you rich</h2><p>Leading HVAC company Carrier Global came out of the former United Technologies. The case for the stock hinges on the company's ability to cut costs and grow revenue.</p><p>Management is on track with its so-called \"Carrier 700\" plan to cut $700 million from annual costs by 2022. The cost cuts will come from consolidating and shifting toward low-cost suppliers, lowering factory costs by increasing automated production, and lowering administrative costs by increasing the number of employees performing shared service roles.</p><p>Still, it's not just about cost-cutting. Carrier has plenty of growth opportunities. The coronavirus pandemic has led to a surge in residential orders, and higher-quality HVAC providers have a growth opportunity from commercial customers looking to increase air quality and ventilation in their buildings in a post-pandemic world.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F621509%2Fcomm-buildings.jpg&w=700&op=resize\" tg-width=\"700\" tg-height=\"503\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><p>Also, the HVAC industry's leading players have an opportunity to increase equipment and service sales through the adoption of digital technologies that should improve service levels. Meanwhile, rising global temperatures (particularly in cities as urbanization occurs), increasing regulatory requirements, and the growth of the middle class in emerging economies should all support long-term HVAC demand.</p><p>Analysts have the company trading at an enterprise value to EBITDA multiple of 12.8 times in 2022, when the Carrier 700 plan ends. That's a good value for a company with high-single-digit earnings growth potential.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Make You Rich</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Make You Rich\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 20:25 GMT+8 <a href=https://www.fool.com/investing/2021/04/21/3-stocks-that-could-make-you-rich/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With stock price rises of 76% to 209% over the last year, agriscience experts Corteva (NYSE:CTVA), engineering consultancy AECOM (NYSE:ACM), and heating, ventilation, and air-conditioning experts (...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/3-stocks-that-could-make-you-rich/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACM":"Aecom Technology Corporation"},"source_url":"https://www.fool.com/investing/2021/04/21/3-stocks-that-could-make-you-rich/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129713088","content_text":"With stock price rises of 76% to 209% over the last year, agriscience experts Corteva (NYSE:CTVA), engineering consultancy AECOM (NYSE:ACM), and heating, ventilation, and air-conditioning experts (HVAC) company Carrier Global (NYSE:CARR) have arguably already made investors rich. However, I think there could be a lot more to come from all three in the coming years. Here's why.Why Corteva can make you richCorteva was created out of the DowDuPont merger. DuPont's expertise in seeds was combined with Dow's crop protection specialty to create a company that generates around 55% of its sales from seeds and traits and 45% from crop protection. The investment case for the stock rests on the three interrelated factors.Image source: Getty Images.First, management will continue to execute its plan to cut structural costs and enhance productivity following the merger. For example, Corteva generated $230 million in cost and productivity actions in 2020, and management expects a further $250 million in 2021. For reference, operating earnings before interest, taxation, depreciation, and amortization (EBITDA) was $2.1 billion in 2020, so these cost actions are significant and help to enable growth investments.Second, Corteva has a significant opportunity to expand profit margins by reducing its royalty payments to other companies as it grows the share of its seed sales coming from seeds using its own germplasm and in-licensed traits. Management sees an opportunity to cut royalty payments by $400 million over time. Also, Corteva plans to significantly increase the share of its crop protection sales coming from patented and \"differentiated\" sources from 14% and 10% in 2018 to 34% and 16% by 2023 -- something that should increase the quality of its earnings and give it more pricing power.Third, Corteva aims to grow sales of its Enlist soybean seeds and crop protection system. Competition is fierce, but management believes it can achieve a 50% market share over time compared to 20% share in 2020.All told, the company has plenty of revenue and margin expansion opportunities, and analysts expect it to increase EBITDA by 50% to more than $3 billion by 2023, potentially putting the stock at an enterprise value (market cap plus debt) to EBITDA multiple of 10 times EBITDA in 2023. That's an excellent multiple for a stock with double-digit earnings growth prospects.Why AECOM can make you richThe case for engineering consultancy AECOM rests on a combination of confidence that an infrastructure bill will boost its long-term growth prospects and that its restructuring plan will be executed successfully.Image source: Getty Images.AECOM's three biggest end markets are transportation, facilities, and environment and water. As such, it's a play on an infrastructure bill not least as the U.S. needs to upgrade roads, transportation facilities, bridges, dams, and other water infrastructure. Also, increasing environmental regulation ensures long-term demand growth for AECOM's environmental services.AECOM has a growth opportunity through its ongoing plan to slim down and focus on its core competencies. It's a playbook established by its peer Jacobs Engineering Group, and if AECOM can achieve its aim, then there's no reason why it can't close the valuation gap with Jacobs.Data by YChartsWhy Carrier Global can make you richLeading HVAC company Carrier Global came out of the former United Technologies. The case for the stock hinges on the company's ability to cut costs and grow revenue.Management is on track with its so-called \"Carrier 700\" plan to cut $700 million from annual costs by 2022. The cost cuts will come from consolidating and shifting toward low-cost suppliers, lowering factory costs by increasing automated production, and lowering administrative costs by increasing the number of employees performing shared service roles.Still, it's not just about cost-cutting. Carrier has plenty of growth opportunities. The coronavirus pandemic has led to a surge in residential orders, and higher-quality HVAC providers have a growth opportunity from commercial customers looking to increase air quality and ventilation in their buildings in a post-pandemic world.Image source: Getty Images.Also, the HVAC industry's leading players have an opportunity to increase equipment and service sales through the adoption of digital technologies that should improve service levels. Meanwhile, rising global temperatures (particularly in cities as urbanization occurs), increasing regulatory requirements, and the growth of the middle class in emerging economies should all support long-term HVAC demand.Analysts have the company trading at an enterprise value to EBITDA multiple of 12.8 times in 2022, when the Carrier 700 plan ends. That's a good value for a company with high-single-digit earnings growth potential.","news_type":1},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
